Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy
Standard
Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. / Oing, C; Bristow, R G.
In: ESMO OPEN, Vol. 8, No. 2, 04.2023, p. 101194.Research output: SCORING: Contribution to journal › Editorial › Research
Harvard
Oing, C & Bristow, RG 2023, 'Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy', ESMO OPEN, vol. 8, no. 2, pp. 101194. https://doi.org/10.1016/j.esmoop.2023.101194
APA
Oing, C., & Bristow, R. G. (2023). Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. ESMO OPEN, 8(2), 101194. https://doi.org/10.1016/j.esmoop.2023.101194
Vancouver
Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. ESMO OPEN. 2023 Apr;8(2):101194. https://doi.org/10.1016/j.esmoop.2023.101194
Bibtex
@article{771cd68e578f431f95eea473fae4f552,
title = "Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy",
keywords = "Male, Humans, Prostatic Neoplasms/drug therapy, Docetaxel, Hormones",
author = "C Oing and Bristow, {R G}",
year = "2023",
month = apr,
doi = "10.1016/j.esmoop.2023.101194",
language = "English",
volume = "8",
pages = "101194",
journal = "ESMO OPEN",
issn = "2059-7029",
publisher = "BMJ PUBLISHING GROUP",
number = "2",
}
RIS
TY - JOUR
T1 - Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy
AU - Oing, C
AU - Bristow, R G
PY - 2023/4
Y1 - 2023/4
KW - Male
KW - Humans
KW - Prostatic Neoplasms/drug therapy
KW - Docetaxel
KW - Hormones
U2 - 10.1016/j.esmoop.2023.101194
DO - 10.1016/j.esmoop.2023.101194
M3 - Editorial
C2 - 36947986
VL - 8
SP - 101194
JO - ESMO OPEN
JF - ESMO OPEN
SN - 2059-7029
IS - 2
ER -
